{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T03:52:36Z","timestamp":1787457156307,"version":"build-2736575974"},"reference-count":9,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"abstract":"<jats:p>A 69-year-old Caucasian woman with a 15-year history of refractory chronic lymphocytic B-cell leukaemia (CLL), treated with alemtuzumab in the past 10\u2005months presented with a subacute right foot drop. Initial evaluation with a brain CT scan, lumbosacral MRI, nerve conduction studies and LP was negative. In the following months, progressive right hemibody weakness and dysarthria developed. Brain MRI showed a bilateral parasagittal frontal lesion. Alemtuzumab treatment was withdrawn. Progressive multifocal leukoencephalopathy (PML) was confirmed by PCR. Attempted antiviral therapies proved fruitless. Inexorable clinical deterioration ensued and the patient passed away 10\u2005months after the presentation. This case report intends to call attention for PML as a potential fatal complication of severe immunosuppression, including the possible role of new monoclonal antibodies (such as alemtuzumab) in its pathogenesis.<\/jats:p>","DOI":"10.1136\/bcr-2013-201781","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T10:10:09Z","timestamp":1389175809000},"page":"bcr2013201781","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":35,"title":["Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab"],"prefix":"10.1136","volume":"2014","author":[{"given":"Lu\u00eds","family":"Isidoro","sequence":"first","affiliation":[{"name":"Department of Neurology, Coimbra Hospital and University Centre, Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Pires","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital de Santo Esp\u00edrito, Angra do Hero\u00edsmo, Azores, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds","family":"Rito","sequence":"additional","affiliation":[{"name":"Department of Haematology, Coimbra Hospital and University Centre, Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Cordeiro","sequence":"additional","affiliation":[{"name":"Department of Neurology, Coimbra Hospital and University Centre, Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2014,1,8]]},"reference":[{"key":"2025082701504492000_2014.jan08_1.bcr2013201781.1","doi-asserted-by":"publisher","DOI":"10.1212\/01.CON.0000423852.70641.de"},{"key":"2025082701504492000_2014.jan08_1.bcr2013201781.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.10.005"},{"key":"2025082701504492000_2014.jan08_1.bcr2013201781.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61769-3"},{"key":"2025082701504492000_2014.jan08_1.bcr2013201781.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61768-1"},{"key":"2025082701504492000_2014.jan08_1.bcr2013201781.5","first-page":"e2012043","article-title":"Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of literature","volume":"4","author":"D'Souza","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025082701504492000_2014.jan08_1.bcr2013201781.6","doi-asserted-by":"publisher","DOI":"10.1086\/504811"},{"key":"2025082701504492000_2014.jan08_1.bcr2013201781.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2008.12.010"},{"key":"2025082701504492000_2014.jan08_1.bcr2013201781.8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1017\/S0317167100012105","article-title":"Monoclonal antibodies and progressive multifocal leukoencephalopathy","volume":"38","author":"Keene","year":"2011","journal-title":"Can J Neurol Sci"},{"key":"2025082701504492000_2014.jan08_1.bcr2013201781.9","unstructured":"Biogen Idec Medical Affairs. TYSABRI (natalizumab) Benefit\/Risk Update & PML Risk Stratification Information for Healthcare Professionals , Update June 2013, 2013."}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2013-201781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:50:55Z","timestamp":1756284655000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2013-201781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,8]]},"references-count":9,"alternative-id":["10.1136\/bcr-2013-201781"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2013-201781","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,8]]}}}